Were Michael Farrell’s ResMed (RMD) share sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Such pre-arranged plans schedule trades in advance, framing these sales as part of a pre-planned trading program.

ResMed CEO exercises options, sells 4,991 shares

RESMED INC Chairman and CEO Michael J. Farrell reported an exercise-and-sale transaction in company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RESMED INC Chairman and CEO Michael J. Farrell reported an exercise-and-sale transaction in company stock. On June 8, 2026, he exercised options to acquire 4,991 shares of ResMed Common Stock at $146.34 per share and sold the same 4,991 shares in open-market trades at a $193.962 weighted average price. The sales were executed in multiple trades between $192.605 and $194.715 under a pre-arranged Rule 10b5-1 plan adopted October 31, 2024. Following these transactions, he directly held 466,256 ResMed shares, with 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust and 24,957 stock options remaining outstanding.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,991 shares ($238K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($968K)

Approx. gross sale proceeds $968K

Approx. exercise cost $730K

Approx. pre-tax spread $238K

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	4,991	$0.00	$0.00
Exercise	ResMed Common Stock	4,991	$146.34	$730K
Sale	ResMed Common Stock	4,991	$193.962	$968K
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 24,957 contracts (Direct); ResMed Common Stock — 466,256 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (3)

F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2. This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price.
F3. Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.

Key Figures

Shares sold: 4,991 shares Weighted average sale price: $193.962 per share Option exercise price: $146.34 per share +4 more

7 metrics

Shares sold 4,991 shares Open-market sale of ResMed Common Stock on June 8, 2026

Weighted average sale price $193.962 per share Open-market sales executed between $192.605 and $194.715

Option exercise price $146.34 per share Exercise of options for 4,991 ResMed Common Stock shares

Direct holdings after transaction 466,256 shares ResMed Common Stock directly owned by CEO after June 8, 2026

Indirect trust holdings 2,090 shares Held through Lisette and Michael Farrell Family Trust

Options remaining 24,957 options ResMed Common Stock options following the reported exercise

ESPP shares 32.671 shares Purchased April 30, 2026 via ResMed Employee Stock Purchase Plan

Key Terms

Rule 10b5-1 plan, weighted average sale price, ResMed Employee Stock Purchase Plan, derivative security, +1 more

5 terms

Rule 10b5-1 plan financial

"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

ResMed Employee Stock Purchase Plan financial

"Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan."

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed (RMD) CEO Michael Farrell report?

ResMed CEO Michael Farrell reported an option exercise-and-sale. He exercised options for 4,991 ResMed Common Stock shares at $146.34 each, then sold the same 4,991 shares in open-market trades at a $193.962 weighted average price on June 8, 2026.

How many ResMed (RMD) shares did the CEO sell and at what price?

Michael Farrell sold 4,991 ResMed Common Stock shares. The transactions occurred in multiple trades between $192.605 and $194.715 per share, resulting in a $193.962 weighted average sale price disclosed in the Form 4 footnotes.

How many ResMed (RMD) shares does the CEO hold after this Form 4 transaction?

After the reported transactions, Michael Farrell directly held 466,256 ResMed Common Stock shares. He also had 2,090 shares held indirectly via the Lisette and Michael Farrell Family Trust, in addition to remaining stock options outstanding.

What ResMed stock options did Michael Farrell exercise in this Form 4?

He exercised options covering 4,991 ResMed Common Stock shares at a $146.34 exercise price. These options, originally exercisable from November 11, 2020 and expiring November 21, 2026, decreased his option balance to 24,957 options following the exercise.

Does the Form 4 mention ResMed’s Employee Stock Purchase Plan (ESPP)?

Yes. A footnote explains that Michael Farrell’s holdings include 32.671 ResMed shares purchased on April 30, 2026 through the ResMed Employee Stock Purchase Plan, adding detail on how a portion of his share position was accumulated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/09/2026 - 02:26 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last)

(First)

(Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	06/08/2026		M⁽¹⁾		4,991	A	$146.34	471,214	D
ResMed Common Stock	06/08/2026		S⁽¹⁾		4,991	D	$193.962⁽²⁾	466,256⁽³⁾	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock Options	$146.34	06/08/2026		M			4,991	11/11/2020	11/21/2026	ResMed Common Stock	4,991	$0	24,957	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price.

3. Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.

	/s/ Michael J. Farrell, Chairman and CEO	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR